By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GnuBio announced today it obtained a worldwide license to microfluidics- and emulsion-based methods for nucleic acid analysis.

The technology, which was licensed from the laboratory of David Weitz, one of the founders of GnuBio, will be used by the startup firm to develop its DNA sequencer.

Weitz is a professor of physics and applied physics at Harvard University.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.